Day: September 1, 2020

AB „Ignitis grupė“ (toliau – „Ignitis grupė“ ir Bendrovė), juridinio asmens kodas: 301844044, registruotos buveinės adresas: Žvejų g. 14, Vilnius. Bendra  „Ignitis grupė“ išleistų obligacijų nominali vertė 900 000 000 EUR; ISIN kodai: XS1646530565; XS1853999313; XS2177349912.Bendrovė informuoja, kad 2020 m. rugpjūčio 31 d. juridinių asmenų registre buvo įregistruota nauja Bendrovės įstatų redakcija, kuria pakeistas Bendrovės išleistų akcijų skaičius ir nominali vertė, nekeičiant įstatinio kapitalo dydžio.Kaip Bendrovė skelbė anksčiau, 2020 m. rugpjūčio 26 d. jos vienintelio akcininko teises įgyvendinanti Lietuvos Respublikos finansų ministerija (toliau – Finansų ministerija) priėmė sprendimą pakeisti Bendrovės išleistų akcijų nominalią vertę ir akcijų skaičių. Vadovaujantis Finansų ministerijos sprendimu, vienos paprastosios vardinės...

First investigational trial of a drug-biologic bone graft for spine fusionPhase 2 trial in the U.S. compares Fibrin-PTH (KUR-113) with local autograftPrimary endpoint is radiographic interbody fusion at 12 monthsPotential to address a major commercial opportunitySCHLIEREN (ZURICH), Switzerland, Sept. 01, 2020 (GLOBE NEWSWIRE) — Kuros Biosciences, a leader in next generation bone graft technologies, today announced that the first patient has been treated in the STRUCTURE trial, investigating Fibrin-PTH (KUR-113) for transforaminal lumbar interbody fusion (TLIF) procedures in patients with degenerative disc disease. The first patient was treated by Dr Richard Todd Allen, principal investigator at University California San Diego. The STRUCTURE trial is conducted under an open Investigational New Drug (IND) for spinal fusion, which...

Detects, confirms and differentiates HIV-1 and HIV-2 infections providing clinicians with critical diagnostic data for personalised management of patients with HIV – from appropriate counseling on disease differences to targeted therapySupports rapid molecular detection of acute HIV infection, which is critical in curbing further disease transmissionCombines confirmatory HIV testing and HIV-1/HIV-2 differentiation into one single testBasel, 1 September 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced U.S. Food and Drug Administration (FDA) approval for the cobas® HIV-1/HIV-2 Qualitative Test for use on the fully automated cobas® 6800/8800 Systems in the U.S. The test provides healthcare professionals with a single result to confirm HIV diagnosis and differentiate HIV-1 and HIV-2, an important distinction needed to...

ROTTERDAM, The Netherlands (1 September 2020) – IMCD N.V. (“IMCD” or “Company”), a leading distributor of speciality chemicals and ingredients, today announces that it has successfully signed an agreement to acquire 100% of the shares in the South African distributor Siyeza Fine Chem Propriety Limited (“Siyeza”).Siyeza, based in Johannesburg, was founded in 2007 and is a leading distributor of pharmaceutical, veterinary, food, and personal care speciality chemical ingredients in South Africa. The company has 27 employees and generated a revenue of €11.7 million in 2019 through its representation of world-leading producers from Europe and Asia.The closing of the transaction is subject to customary regulatory review and is expected in December 2020.– xxx –About IMCD N.V. IMCD is a market leader in the sales, marketing,...

WISeKey and ARHT Media Team Up for the First Ever Trusted HoloPresence Investor Meeting to Be Held at The NASDAQ MarketSite in Times Square in NYC on November 17Eliminating the need for physical contact and long-distance travel, Trusted HoloPresence meetings will reduce environmental impact and allow for social distancing to stop the spread of COVID-19.GENEVA, NEW YORK & TORONTO, September 1, 2020 — WISeKey International Holding Ltd (“WISeKey,” SIX: WIHN / Nasdaq: WKEY), a leading cybersecurity and IoT company and ARHT Media Inc. (“ARHT” or “the Company”) (TSXV:ART), a global leader in the development, production and distribution of high-quality, low latency hologram and digital content for online and in-person communication, today announced a partnership where WISeKey will provide third-party...

Oxurion NV Reports First Patient Dosed in Phase 2 study evaluating THR-149 for treatment of Diabetic Macular Edema (DME)                                                        THR-149 is a potent plasma kallikrein inhibitor in development for DME for up to 40% of patients who respond sub-optimally to anti-VEGF therapy.       Part A of the study will assess the optimal dose from 3 different dose levels of 3 THR-149 injections – read out anticipated around mid-2021Part B of the study will then evaluate the efficacy and safety of the selected optimal dose of THR-149 versus aflibercept for the treatment of DME – read out anticipated in first half of 2023              Leuven, Belgium, 1 September – 07.00 AM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company engaged in the development of next-generation therapies to treat...

2025 target to increase patients reached in LMICs with strategic innovative medicines by 200% and the Novartis Flagship Programs by 50% – bringing potential reach to over 23 million patients across these initiatives Enhanced target for full carbon neutrality across all company operations and entire supply chain by 20301 New collaboration with the African Union initiated Africa Medical Supplies Platform to aid supply of Novartis COVID-19 Pandemic Response Portfolio Company completed enrollment in the CAN-COVID Phase III clinical trial with expected readout in Q4 2020             Basel, September 1, 2020 — Novartis will host a virtual investor event today to provide a comprehensive overview of the company’s progress in its Environmental, Social and Governance (ESG) strategy.“ESG is a key strategic priority for the Novartis Board and...

PRESS RELEASE: 1 September 2020, 07:00 CEST Biocartis Expands Collaboration with LifeArcMechelen, Belgium, and London, UK, 1 September 2020 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces the expansion of its collaboration with LifeArc, a UK based independent medical research charity, with a new agreement aimed at the development of highly innovative prototype assays in the field of infectious and immune related diseases on Biocartis’ fully automated molecular diagnostics platform Idylla™.The new licence and development agreement is an extension of the existing partnership1 between LifeArc and Biocartis, which is today focused on the development and the commercialization of the Idylla™ ABC (Advanced Breast Cancer) assay2. This assay is positioned...

PERSBERICHT: 1 september 2020, 07:00 CEST Biocartis breidt samenwerking met LifeArc uitMechelen, België, en Londen, VK, 1 september 2020 – Biocartis Group NV (de ‘Vennootschap’ of ‘Biocartis’), een innovatief bedrijf in de moleculaire diagnostiek (Euronext Brussels: BCART), kondigt vandaag de uitbreiding aan van zijn samenwerking met LifeArc, een in het VK gebaseerde onafhankelijke liefdadigheidsinstelling voor medisch onderzoek. De nieuwe overeenkomst is gericht op de ontwikkeling van hooginnovatieve prototype tests in het domein van infectueuze- en immuungerelateerde ziekten, voor gebruik op Biocartis’ volledig geautomatiseerde moleculair diagnoseplatform Idylla™.De nieuwe licentie- en ontwikkelingsovereenkomst is een uitbreiding van de bestaande samenwerking1 tussen LifeArc en Biocartis, die vandaag is gericht op de ontwikkeling en commercialisering...

PARIS  – September 1, 2020 – Sanofi today announced that the global Phase 3 trial investigating intravenously administered Kevzara® (sarilumab) at a dose of 200 mg or 400 mg[a]  in severely or critically ill[b]  patients hospitalized with COVID-19 did not meet its primary endpoint and key secondary endpoint[c] when Kevzara was compared to placebo added to usual hospital care. The 420-patient randomized trial was conducted outside the U.S. in Argentina, Brazil, Canada, Chile, France, Germany, Israel, Italy, Japan, Russia and Spain (86 in placebo, 161 in 200 mg, and 173 in 400 mg arms).“Although this trial did not yield the results we hoped for, we are proud of the work that was achieved by the team to further our understanding of the potential use of Kevzara for the treatment of COVID-19,” said John Reed, M.D., Ph.D., Global Head of Research...